Table 2.
RBD-IgG and neutralizing antibodies (NA) following the second vaccine dose, GMT.
| Underlying disease | RBD-IgG N | Positive RBD-IgG after 2nd Vx n/N (%) | RBD-IgG GMT (95% CI) | NA* GMT (95% CI) |
|---|---|---|---|---|
| Controls** | 272 | 269/272 (98.9) | 5.98 (5.70–6.28) | 474.0 (403.2–557.3) |
| HIV | 156 | 154/156 (98.7) | 5.14 (4.84–5.46) | 467.60 (382.5–571.7) |
| Solid malignancies | 90 | 75/90 (83.3) | 3.17 (2.56–3.92) | 270.0 (154.8–471.0) |
| Multiple myeloma | 187 | 149/187 (79.7) | 2.76 (2.38–3.20) | 297.7 (191.8–462.1) |
| HSCT | 111 | 83/111 (74.8) | 2.55 (2.03–3.21) | 653.8 (353.3–1210) |
| Liver transplant | 36 | 25/36 (69.4) | 2.14 (1.46–3.14) | 264.6 (121.8–574.9) |
| Myelodysplastic disorders | 43 | 26/43 (60.5) | 1.54 (1.04–2.28) | 362.0 (164.9–795.0) |
| CLL/NHL | 188 | 96/188 (51.0) | 1.18 (0.97–1.43) | 261.4 (166.8–409.6) |
| Kidney transplant | 111 | 50/111 (45.0) | 1.00 (0.80–1.24) | 89.5 (51.1–156.7) |
| Heart transplant | 80 | 15/80 (18.8) | 0.55 (0.44–0.68) | 53.8 (24.1–120.4) |
| All patients | 1002 | 673/1002 (67.2) | 1.98 (1.83–2.14) | 313.2 (267.2–367.1) |
⁎
Only samples with neutralizing antibody titers above the cutoff (> 8) were included in the analysis for GMT-NA, ** Controls – immunocompetent healthcare workers, RBD - receptor binding domain, Vx - vaccination, GMT- geometric mean titer, CI - confidence interval, CLL - chronic lymphocytic leukemia, NHL - non-Hodgkin's lymphoma, HIV - human immunodeficiency virus, HSCT - hematopoietic stem cell transplantation.